ipaom

Archives of Medicine

ISSN - 1989-5216

Research Article - (2018) Volume 10, Issue 2

View PDF Download PDF

Superiority of Carboplatin-Based Doublets to Cisplatin-Based Doublets among Medicare Patients Aged 70 and Older with Advanced Lung Cancer

 

Author info »

Abstract

Background: Some evidence suggests that cisplatin-based chemotherapy doublet regimens are more effective than the less toxic carboplatin-based doublet regimens for patients with advanced non-small cell lung cancer (NSCLC), but their effectiveness among elderly cancer patients who are treated in usual care settings is not known.

Methods: We identified 13,406 elderly Medicare patients who were diagnosed with stage IV NSCLC between the years 1995-2007 in SEER regions and treated with either a cisplatin-based or a carboplatin-based doublet chemotherapy regimen in the subsequent six months. Using propensity score weighting, we balanced the two treatment cohorts with respect to observable attributes. We then estimated survival and morbidity according to treatment.

Findings: Overall, patients treated with cisplatin-based doublets lived two weeks longer on average than patients treated with carboplatin-based doublets (i.e., 7.4 months vs. 7.0 months, p=0.05). For patients >70 years of age, first-line therapy with cisplatin-based doublet chemotherapy regimens was associated with increased post-treatment morbidity and lack of survival advantage compared to carboplatin-based doublet therapies.

Interpretations: For patients >70 years of age first-line therapy with carboplatinbased doublet chemotherapy regimens are preferable to cisplatin-based doublet therapies given the similar survival and lower risk of hospitalization.

References

  1. National Cancer Institute: Surveillance, Epidemiology and End Results Program (2014) Cancer stat fact: Lung and bronchus cancer.
  2. Non-small cell lung cancer collaborative group (1995) Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized trials. BMJ 311: 899-909.
  3. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, et al. (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367.
  4. Wozniak AJ, Crowley JJ, Balcerzak SP (1996) Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): Report of a southwest oncology group study (SWOG-9308). Proc ASCO 15: 374.
  5. NSCLC Meta-analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26: 4617-4625.
  6. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
  7. Chen YM, Perng RP, Tsai CM, Whang-Peng J (2006) A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly. J Throac Oncol 1: 141-145.
  8. Langer C, Li S, Schiller J, Tester W, Rapoport BL, et al. (2007) Randomized phase II trial of paclitaxel plus carboplatin gemcitabine plus cisplatin in eastern cooperative oncology group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 25: 418-423.
  9. Jiang J, Liang X, Zhou X, Huang R, Chu Z (2007) A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57: 348-358.
  10. Rosell R, Gatzemeier U, Betticher DC, Keppler U,  Macha HN, et al. (2002) Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 13: 1539-1549.
  11. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, et al. (2002) Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 99: 847-57.
  12. de Castria TB, da Silva EMK, Gois AFT, Riera R (2013) Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev 8: CD009256.
  13. Luo J, Leaw SJ, Xu Y, Zheng D (2011) Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer. Med Oncol 28: 1418-1424.
  14. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, et al. (2001) Effectiveness of chemotherapy for advanced lung cancer in the elderly: Instrumental variable and propensity analysis. J Clin Oncol 19: 1064-1070.
  15. Davidoff AJ, Tang M, Seal B, Edelman MJ (2010) Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 28: 2197-2197.
  16. Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, et al. (2014) Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. J Thorac Oncol  9: 702-709.
  17. Landrum MB, Keating NL, Lamont EB, Bozeman SR, Krasnow SH, et al. (2012) Survival of older patients with cancer in the veterans’ health administration versus fee-for-service Medicare. J Clin Oncol 30: 1072-1079.
  18. Lamont EB, Landrum MB, Keating NL, Archer L, Lan L, et al. (2010) Differences in clinical trial patients' attributes and outcomes according to enrollment setting. J Clin Oncol 28:215-221.
  19. Agha Z, Lofgren RP, Van Ruiswyk JV, Layde PM (2000) Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med 160: 3252.
  20. Nelson KM (2006) The burden of obesity among a national probability sample of Veterans. J Gen Intern Med 21: 915-919.
  21. Kazis LE, Miller DR, Clark J, Skinner K, Lee A, et al. (1998) Health-related quality of life in patients served by the department of veterans affairs: Results from the veterans health study. Arch Intern Med 158: 626-632.
  22. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, et al. (1997) SEER cancer statistics review, 1973-1994. Bethesda, National Cancer Institute.
  23. National Cancer Institute: Surveillance, Epidemiology, and End Results Program (2014) Overview of the Seer Program.
  24. Nattinger AB, McAuliffe TL, Schapira MM (1997) Generalizability of the surveillance, epidemiology and end results registry population: Factors relevant to epidemiologic and health care research. J Clin Epidemiol 50: 939-945.
  25. Lamont EB, Lan L (2014) Sensitivity of Medicare claims data for measuring use of standard multi-agent chemotherapy regimens. Medical Care 52: e15-20.
  26. Lamont EB, He Y, Saltz L, Muss H, Zaslavsky AM (2014) Hospital-based health care use correlates with incidence of treatment-related adverse events among elderly Medicare patients treated on adjuvant chemotherapy trials (Alliance 70802). J Geriatr Oncol 5: 230-237.
  27. Eichler AF, Lamont EB (2009) Utility of administrative claims data for the study of brain metastases: a validation study. J Neurooncol 95: 427-431.
  28. Rosenbaum PR, Rubin DB (1984) Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79: 516-524.
  29. Rosenbaum PR, Rubin DB (1984) The central role of the propensity score in observational studies for causal effects. Biometrika 70: 41-55.
  30. Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39: 33-38.
  31. Rubin DB, Thomas N (1996) Matching using estimated propensity scores: Relating theory to practice. Biometrics 52: 249-64.
  32. Smith HL (1997) Matching with multiple controls to estimate treatment effects in observational studies. Sociol methodol: 325-353.
  33. Sagerup CM, Smastuen M, Johannesen TB, Helland A, Brustugun OT (2012) Increasing age and carcinoma not other specified: A 20-year population study of 40,118 lung cancer patients. J Thorac Oncol 7: 57-63.
  34. Ou SH, Zell JA (2009) Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 4: 1202-1211.
  35. Lamont EB, Schilsky RL, He Y, Muss H, Cohen H, et al.  (2015) Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst 107: 1-7.

Author Info

 

, DOI: 10.21767/1989-5216.1000264

Copyright:This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

iomcworld scan

Journal Highlights

Journal Flyer

Flyer

+44-745-639-6942